Investment analysts at Cantor Fitzgerald began coverage on shares of Volcano Corporation (NASDAQ:VOLC), in a note issued to investors on Tuesday,TheFlyOnTheWall.com reports. The firm set a “hold” rating and a $21.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 15.45% from the stock’s previous close. Volcano Corporation (NASDAQ:VOLC), net profit margin is -10.56% and weekly performance is -6.56%. On last trading day company shares ended up $16.45. Analysts mean target price for the company is $22.08. Volcano Corporation (NASDAQ:VOLC), distance from 50-day simple moving average (SMA50) is -7.27%.
Shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), have been given a consensus recommendation of “Hold” by the thirteen analysts that are presently covering the company,StockRatingsNetwork.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $74.45. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), fell 6.56% in last trading session and ended the day on $28.91. AEGR, Gross Margin is 89.90% and its return on assets is -44.20%. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), quarterly performance is -32.63%.
On July 01, 2014, Cerus Corporation (NASDAQ:CERS), announced that it has entered into a $30 million growth capital credit facility with Oxford Finance LLC. Cerus received an immediate $10 million loan at closing on June 30, 2014. The Company has the option to draw another $10 million upon approval of its U.S. Premarket Approval (PMA) submissions for the INTERCEPT Blood System for either platelets or plasma. The approval also triggers a third $10 million tranche which is available at the Company’s option between July 1, 2015 and December 31, 2015, subject to achievement of certain specified consolidated revenue milestones. Cerus Corporation (NASDAQ:CERS), shares moved down 4.81% in last trading session and was closed at $3.76, while trading in range of $3.66 – 3.95. Cerus Corporation (NASDAQ:CERS), year to date (YTD) performance is -41.71%.
On July 03, 2014, MELA Sciences Inc (NASDAQ:MELA), developer of theMelaFind ® system, an optical diagnostic device approved for use in the U.S. and theEuropean Union to assist dermatologists in melanoma diagnosis, announced that its board of directors has approved a one-for-ten reverse stock split of the Company’s common stock to become effective at 5 p.m., Eastern Time, July 9, 2014. The Company will file an amendment to its Certificate of Incorporation on that date as authorized by the stockholders at the Company’s annual meeting held on May 15, 2014. The Company’s common stock is expected to commence trading on a post-reverse stock split basis on July 10, 2014. The common stock will continue to trade under the symbol “MELA.” MELA Sciences Inc (NASDAQ:MELA), ended the last trading day at $0.277. Company weekly volatility is calculated as 8.73% and price to cash ratio as 1.79. MELA Sciences Inc (NASDAQ:MELA), showed a negative weekly performance of 13.50%.